Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
Therion Biologics Corp is developing PROSTVAC-VF-TRICOM, a prime-boost vaccine regimen that consists of a priming injection with a recombinant attenuated vaccinia virus expressing PSA and TRICOM (the company's proprietary triad of costimulatory molecules: ICAM-1, B7.1 and lymphocyte function-associated antigen-3), and a booster injection with a fowlpox virus expressing the same combination, for the potential treatment of prostate cancer. Phase II clinical trials are underway.
Doehn
Christian
C
University of Lübeck Medical School, Department of Urology, Ratzeburger Allee 160, 23538 Lübeck, Germany. doehn@medinf.mu-luebeck.de
Kausch
Ingo
I
Böhmer
Torsten
T
Sommerauer
Martin
M
Jocham
Dieter
D
D019496:Cancer Vaccines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D010330:Patents as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D019496:Cancer Vaccines